| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
Anti-microtubule agents such as vinorelbine and paclitaxel, which are extensively used in the treatment of lung cancers, activate mitotic spindle checkpoint. Although defects of the mitotic spindle checkpoint are thought to play a role in the genesis of chromosome instability, we previously reported its frequent impairment in human lung cancer cell lines. In this study, we examined a panel of 13 human cancer cell lines comprising 11 lung and 2 other cancers and found a significant difference in the resistance to apoptosis induced by anti-microtubule agents between mitotic spindle checkpoint-impaired and -proficient cancer cell lines. This finding was in marked contrast to a lack of such correlation with a DNA damaging agent, cis-platin. Interestingly, anti-microtubule agent-induced apoptosis in mitotic spindle checkpoint-proficient cell lines, NCI-H460 and A549, was shown to be markedly reduced by staurosporine treatment in association with the shortened mitotic arrest, whereas various inhibitors of caspases seemed to have very modest effects. Taken together, these findings suggest the potential involvement of mitotic spindle checkpoint in the induction of apoptosis by anti-microtubule agents in human lung cancers, warranting further studies on the underlying mechanisms.
This article has been cited by other articles:
 |
|
 |
|
  J. Doles and M. T. Hemann Nek4 Status Differentially Alters Sensitivity to Distinct Microtubule Poisons Cancer Res., February 1, 2010; 70(3): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zhang, Z. Yan, C. L. Painter, Q. Zhang, E. Chen, M. E. Arango, K. Kuszpit, K. Zasadny, M. Hallin, J. Hallin, et al. PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts Clin. Cancer Res., July 15, 2009; 15(14): 4630 - 4640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nakai, S.-i. Iida, T. Takahashi, T. Tsujita, S. Okamoto, C. Takada, K. Akasaka, S. Ichikawa, H. Ishida, H. Kusaka, et al. K858, a Novel Inhibitor of Mitotic Kinesin Eg5 and Antitumor Agent, Induces Cell Death in Cancer Cells Cancer Res., May 1, 2009; 69(9): 3901 - 3909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stolz, C. Vogel, V. Schneider, N. Ertych, A. Kienitz, H. Yu, and H. Bastians Pharmacologic Abrogation of the Mitotic Spindle Checkpoint by an Indolocarbazole Discovered by Cellular Screening Efficiently Kills Cancer Cells Cancer Res., May 1, 2009; 69(9): 3874 - 3883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shi, J. D. Orth, and T. Mitchison Cell Type Variation in Responses to Antimitotic Drugs that Target Microtubules and Kinesin-5 Cancer Res., May 1, 2008; 68(9): 3269 - 3276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Guo, G. Wu, J. L. Chin, G. Bauman, M. Moussa, F. Wang, N. M. Greenberg, S. S. Taylor, and J. W. Xuan Bub1 Up-Regulation and Hyperphosphorylation Promote Malignant Transformation in SV40 Tag-Induced Transgenic Mouse Models Mol. Cancer Res., December 1, 2006; 4(12): 957 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Yamada and G. J. Gorbsky Spindle checkpoint function and cellular sensitivity to antimitotic drugs Mol. Cancer Ther., December 1, 2006; 5(12): 2963 - 2969. [Full Text] [PDF]
|
|
|
|
|
|
G. M. Chin and R. Herbst Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol. Cancer Ther., October 1, 2006; 5(10): 2580 - 2591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ryo, H. Uemura, H. Ishiguro, T. Saitoh, A. Yamaguchi, K. Perrem, Y. Kubota, K. P. Lu, and I. Aoki Stable Suppression of Tumorigenicity by Pin1-Targeted RNA Interference in Prostate Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7523 - 7531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Vogel, A. Kienitz, R. Muller, and H. Bastians The Mitotic Spindle Checkpoint Is a Critical Determinant for Topoisomerase-based Chemotherapy J. Biol. Chem., February 11, 2005; 280(6): 4025 - 4028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Sun, I. Betzendahl, F. Pacchierotti, R. Ranaldi, J. Smitz, R. Cortvrindt, and U. Eichenlaub-Ritter Aneuploidy in mouse metaphase II oocytes exposed in vivo and in vitro in preantral follicle culture to nocodazole Mutagenesis, January 1, 2005; 20(1): 65 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kanthou, O. Greco, A. Stratford, I. Cook, R. Knight, O. Benzakour, and G. Tozer The Tubulin-Binding Agent Combretastatin A-4-Phosphate Arrests Endothelial Cells in Mitosis and Induces Mitotic Cell Death Am. J. Pathol., October 1, 2004; 165(4): 1401 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakagawa, Y. Hayashita, K. Maeno, A. Masuda, N. Sugito, H. Osada, K. Yanagisawa, H. Ebi, K. Shimokata, and T. Takahashi Identification of Decatenation G2 Checkpoint Impairment Independently of DNA Damage G2 Checkpoint in Human Lung Cancer Cell Lines Cancer Res., July 15, 2004; 64(14): 4826 - 4832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Lee, M. K. Keutmann, M. L. Dowling, E. Harris, G. Chan, and G. D. Kao Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells Mol. Cancer Ther., June 1, 2004; 3(6): 661 - 669. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
